The intent of the HORIZON program was to provide a comprehensive overview of how moderate-to-severe psoriasis is being managed in Canada using immune-targeted therapies. To do so, a faculty of thirty-nine (39) dermatologists from across Canada were convened for 4 meetings throughout 2019 to develop a national treatment strategy, by consensus, based on cases, of bio-naïve as well as bio-experienced patients, presented by participants from their own practices. The faculty received an honorarium from Novartis Canada for their participation in the HORIZON program.
View highlights of the HORIZON program in the series of brief videos below:
- Dr. Howard Yanofsky presents highlights from the HORIZON program: 4 findings on Canadian immune-targeted treatment in psoriasis – https://bit.ly/YanofskyVid [4 min]
- Dr. Ron Vender presents highlights from the HORIZON program, including discussion and conclusions on biologic choices for complicated cases – http://bit.ly/VenderVid [6 min]
- Dr. Mark Kirchhof presents highlights from the HORIZON program, an evolution of Canadian immune-targeted treatment in psoriasis – http://bit.ly/PSOLVEKirchhofVid [6 min]
- Dr. Wayne Gulliver discusses the HORIZON program and the evolution of Canadian immune-targeted treatment in psoriasis – http://bit.ly/PSOLVEGulliverVid [14 min]
These HORIZON videos have been created for and distributed through the PSOLVE+ community. If you are a Canadian physician with an interest in psoriasis and related dermatological conditions, you are invited to sign up for the PSOLVE+ community at http://bit.ly/PSOLVESignup